Birchview Capital, LP
BURLINGTON, VT · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$173.1M2026 Q3
Positions79
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.56.0%
What Changed This Quarter?
Top Holdings
KLAC
Kla
18.8%
BMY
Bristol Myers Squibb
8.1%
LRCX
Lam Research
5.7%
Biodesix
Biodesix
4.9%
CORT
Corcept Therapeutics
3.7%
OVV
Ovintiv
3.6%
RARE
Ultragenyx Pharmaceutical
3.2%
SLDB
Solid Biosciences
3.0%
New / Increased
23 new · 13 increased
RARENEW
Ultragenyx Pharmaceutical
3.2%
Contineum The…NEW
Contineum Therapeutics Inc
1.3%
IRLANEW
Quince Therapeutics
0.7%
VALNNEW
Valneva
0.7%
Annexon (annx…NEW
Annexon Inc (Annx)
0.6%
DFTX
Definium Therapeutics
1.1%
+160.0%
XENE
Xenon Pharmaceuticals
0.9%
+104.4%
BBIO
Bridgebio Pharma
0.7%
+114.4%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.